IgG Antibody Responses to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Their Effective Potential for Disease Diagnosis and Pathological Antigenic Mimicry. — CFSMEATLAS
IgG Antibody Responses to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Their Effective Potential for Disease Diagnosis and Pathological Antigenic Mimicry.
Fonseca, André, Szysz, Mateusz, Ly, Hoang Thien et al. · Medicina (Kaunas, Lithuania) · 2024 · DOI
Quick Summary
Researchers examined immune responses (antibodies) against Epstein-Barr virus in ME/CFS patients to see if these could be used to diagnose the condition. They found that a specific set of 26 antibodies could reliably identify ME/CFS patients whose illness started after an infection, but these antibodies don't appear to explain why the autoimmune problems occur. The findings suggest that while these antibodies might be useful for diagnosis in some patients, they may not be the root cause of ME/CFS.
Why It Matters
This study addresses a critical need in ME/CFS research: identifying biological markers for diagnosis, particularly in the subset of patients whose illness began after infection. Understanding which antibodies distinguish ME/CFS patients could eventually improve diagnosis and help researchers understand disease mechanisms, potentially leading to better treatments.
Observed Findings
A 26-antibody classifier distinguished ME/CFS patients with infectious triggers from healthy controls with 90% accuracy in test datasets
No antibody-based classifier achieved the 85% accuracy threshold when analyzing all ME/CFS patients or non-infectious subgroups
The 26 antibodies selected by the machine learning algorithm showed no significant correlation between their importance in the classifier and sequence homology with human proteins
Different ME/CFS subgroups (infectious vs. non-infectious triggers) showed distinct EBV antibody response patterns
Inferred Conclusions
EBV antibody responses may have diagnostic potential for a specific subset of ME/CFS patients with identifiable infectious triggers
EBV antibody-mediated molecular mimicry is unlikely to be the primary pathological mechanism in ME/CFS, despite immune system involvement
ME/CFS is likely heterogeneous, with different disease triggers (infectious vs. non-infectious) producing distinct immunological profiles
Remaining Questions
Why do only patients with infectious triggers show distinct EBV antibody patterns, and what distinguishes ME/CFS in non-infectious cases?
What mechanisms explain the autoimmune features of ME/CFS if not EBV antibody-driven molecular mimicry?
What This Study Does Not Prove
This study does not prove that EBV antibodies cause ME/CFS or that molecular mimicry explains the disease pathology. The inability to develop a classifier for all ME/CFS patients suggests that EBV antibody patterns alone are not universal diagnostic markers. The findings are correlational and cannot establish causation or identify the underlying mechanisms driving the illness.